BioStock: Ultimovacs updates INITIUM study timeline

The phase II INITIUM trial with Ultimovacs’ universal cancer vaccine UV1 in malignant melanoma was due for a data readout in the first half of 2023. However, disease progression is taking longer than expected, which is a good sign for patients in such a high risk group. The company has thus updated guidance for a readout to the second half of 2023. BioStock spoke with Ultimovacs’ CEO Carlos de Sousa to learn more

Read the interview with Carlos de Sousa at biostock.se:

Ultimovacs updates INITIUM study timeline - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/